PL2542241T3 - Sposoby i kompozycje do leczenia lub zapobiegania objawom wahań hormonalnych - Google Patents

Sposoby i kompozycje do leczenia lub zapobiegania objawom wahań hormonalnych

Info

Publication number
PL2542241T3
PL2542241T3 PL11751180.8T PL11751180T PL2542241T3 PL 2542241 T3 PL2542241 T3 PL 2542241T3 PL 11751180 T PL11751180 T PL 11751180T PL 2542241 T3 PL2542241 T3 PL 2542241T3
Authority
PL
Poland
Prior art keywords
compositions
treating
methods
preventing symptoms
hormonal variations
Prior art date
Application number
PL11751180.8T
Other languages
English (en)
Polish (pl)
Inventor
Jr. George E. Royster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2542241T3 publication Critical patent/PL2542241T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11751180.8T 2010-03-02 2011-03-01 Sposoby i kompozycje do leczenia lub zapobiegania objawom wahań hormonalnych PL2542241T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30963810P 2010-03-02 2010-03-02

Publications (1)

Publication Number Publication Date
PL2542241T3 true PL2542241T3 (pl) 2016-12-30

Family

ID=44531862

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11751180.8T PL2542241T3 (pl) 2010-03-02 2011-03-01 Sposoby i kompozycje do leczenia lub zapobiegania objawom wahań hormonalnych

Country Status (12)

Country Link
US (1) US20110218213A1 (enExample)
EP (1) EP2542241B1 (enExample)
JP (1) JP5839362B2 (enExample)
CN (1) CN102858343B (enExample)
AU (3) AU2011223807B2 (enExample)
BR (1) BR112012022052B1 (enExample)
CA (1) CA2828041C (enExample)
EA (1) EA027350B1 (enExample)
ES (1) ES2574210T3 (enExample)
IL (2) IL221706A (enExample)
PL (1) PL2542241T3 (enExample)
WO (1) WO2011109367A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9616123B1 (en) * 2012-03-05 2017-04-11 Robert L. Knobler Method and compound for treatment of menopausal symptoms
CN107249615B (zh) * 2015-04-07 2021-02-05 株式会社明治 潮热抑制剂
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
WO2020219270A1 (en) * 2019-04-22 2020-10-29 Knobler Robert L Non-hormonal treatment of hot flashes
WO2021108801A2 (en) * 2019-11-15 2021-06-03 Consegna Pharma, Inc. Long acting nmda antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321012A (en) * 1993-01-28 1994-06-14 Virginia Commonwealth University Medical College Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
EP2275089A1 (en) * 1993-11-19 2011-01-19 Alkermes Controlled Therapeutics, Inc. Preparation of biodegradable microparticles containing a biologically active agent
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
DE60034344T2 (de) * 1999-07-22 2008-01-10 University Of Rochester Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6569471B2 (en) * 2000-09-01 2003-05-27 Natumin Pharma Ab Method for the treatment of symptoms related to normal hormonal variations in women
US20050129783A1 (en) * 2001-04-19 2005-06-16 Mccleary Edward L. Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health
US20040259850A1 (en) * 2001-10-31 2004-12-23 Alves Stephen E. Method for treating or preventing symptoms of hormonal variation including hot flashes
UA81423C2 (en) * 2002-08-15 2008-01-10 PRODUCT CONTAINING SRI AND AGONIST OF THE 5HT2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
HUP0303313A2 (hu) * 2003-10-09 2005-07-28 Richter Gedeon Vegyészeti Gyár Rt. Transzdermális gyógyszerkészítmények
US7855195B2 (en) * 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
WO2005120523A1 (en) * 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
US20060122127A1 (en) * 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
EP1898915A4 (en) * 2005-07-06 2009-01-21 Sepracor Inc COMBINATIONS OF ESZOPICLON AND ANTIDEPRESSIVE
MX2008007589A (es) * 2005-12-13 2009-01-27 Trinity Lab Inc Un metodo para tratar eyaculacion prematura en seres humanos.
KR20080097443A (ko) * 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
ES2423485T3 (es) * 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
US9216206B2 (en) * 2008-07-22 2015-12-22 Menogenix, Inc. Methods of treating symptoms associated with menopause and hormonal variations with G-CSF

Also Published As

Publication number Publication date
EP2542241B1 (en) 2016-04-27
US20110218213A1 (en) 2011-09-08
EP2542241A2 (en) 2013-01-09
IL253853B (en) 2019-05-30
AU2011223807B2 (en) 2016-05-12
IL253853A0 (en) 2017-09-28
CA2828041C (en) 2018-04-17
AU2016213776B2 (en) 2018-04-12
IL221706A (en) 2017-08-31
CN102858343B (zh) 2015-11-25
AU2016213776A1 (en) 2016-09-01
WO2011109367A2 (en) 2011-09-09
ES2574210T3 (es) 2016-06-15
EA027350B1 (ru) 2017-07-31
AU2018205147A1 (en) 2018-08-02
AU2011223807A1 (en) 2012-10-18
JP2013521297A (ja) 2013-06-10
WO2011109367A3 (en) 2011-12-29
CN102858343A (zh) 2013-01-02
WO2011109367A4 (en) 2012-02-23
BR112012022052A2 (pt) 2020-07-07
EA201290851A1 (ru) 2013-04-30
BR112012022052B1 (pt) 2021-06-29
JP5839362B2 (ja) 2016-01-06
CA2828041A1 (en) 2011-09-09
EP2542241A4 (en) 2013-11-06

Similar Documents

Publication Publication Date Title
IL267014A (en) Preparations and methods for the treatment of autoimmune diseases and other diseases
EP2603202A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF TAUOPATHIES
IL225471A0 (en) Preparations and methods for the prevention and treatment of cancer
EP2655334A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
EP2771030A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES
ZA201302625B (en) Methods and compositions for treating hemophilia b
EP2603199A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
EP2523944A4 (en) COMPOUNDS AND COMPOSITIONS FOR IMPROVING COGNITION, METHODS OF MAKING THE SAME, AND METHODS OF TREATMENT
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
IL225488A0 (en) Compounds and methods for the treatment of hematological malignancies
IL215592A0 (en) Compositions and methods for the treatment of inflammation
ZA201300388B (en) Compositions and methods for inhibition of the jak pathway
GB201302653D0 (en) Pharmaceutical compositions and methods of treatment
ZA201302746B (en) Compositions and methods of treating pulmonary hypertension
IL253853A0 (en) Methods and preparations for the treatment or prevention of symptoms of hormonal changes
IL214455A0 (en) Methods and compositions for treatment of neovascularization
EP2590674A4 (en) COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
IL216993A0 (en) Compositions and methods for treatment of multiple sclerosis
EP2572730A4 (en) PROCESS FOR PROPHYLAXIS OR TREATMENT OF METABOLIC SYNDROME
IL225483A0 (en) The compositions and methods for the treatment of neoplasia
ZA201303996B (en) Compositions and methods for treating amyloid plaque associated symptoms
ZA201305497B (en) Methods and compositions for preventing and treating osteoarthritis
PL2606032T3 (pl) Kompozycja i sposoby terapii glejakaep
GB2500357B (en) Combination and composition for treating obesity
PH12014501052A1 (en) Methods and compositions for the treatment of diabetes and related symptoms